【News】Notice on participation in the NASDAQ INTERNATIONAL DESIGNATION program

CYBERDYNE Inc. (the “Company”) today announces joining the NASDAQ INTERNATIONAL DESIGNATION program, which was established by the NASDAQ Group on December 9, 2015 EST. As this does not involve financing, such as a listing or issuance of new shares in the United States, the total number of shares outstanding will not increase and the Company’s shares will not be diluted.

As announced on October 13, 2015, the Company has established a Sponsored Level I ADR (American Depositary Receipt) program and investors are able to buy and sell ADR of the Company at OTC markets in the United States from October 13, 2015 EST (See [IR News] 2015.10.13). As the NASDAQ Group recently commenced its new program, NASDAQ INTERNATIONAL DESIGNATION, the Company has decided to participate in this program in order to enhance liquidity for its ADR. Participation in the NASDAQ INTERNATIONAL DESIGNATION enables investors to access information on the Company’s ADR on investor sites such as Nasdaq.com. (http://www.nasdaq.com/symbol/cybqy)

On June 22, 2015, the Company submitted a 510(k) application (Class II) to the Food and Drug Administration for approval of HAL® for Medical Use, one of the Company’s main products, to be classified as a medical device in the United States. After obtaining the approval, the Company expects to expand its business in the United States. Although the Company has, to date, been focusing on investor relations activities overseas, the Company expects that its participation in the NASDAQ INTERNATIONAL DESIGNATION will lead to higher recognition for the Company and its products and further expansion of their investor base.

Please refer to NASDAQ Group’s website for further details on NASDAQ INTERNATIONAL DESIGNATION.
(http://www.business.nasdaq.com/list/international-designation)

This announcement shall not be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.